Akesobio aims to complete the trials of its lead drug candidates and apply for approval to market them between the second half of this year and 2022. Photo: Handout Akesobio aims to complete the trials of its lead drug candidates and apply for approval to market them between the second half of this year and 2022. Photo: Handout
Akesobio aims to complete the trials of its lead drug candidates and apply for approval to market them between the second half of this year and 2022. Photo: Handout

Chinese cancer drug firm Akesobio’s US$330 million IPO – Hong Kong’s largest this year – is oversubscribed 639 times by city’s investors

  • Akesobio’s HK$2.58 billion IPO sees HK$166.5 billion in investors’ funds locked up
  • Hard to know if popularity is driven by short-term speculation, analyst says

Topic |   IPO
Akesobio aims to complete the trials of its lead drug candidates and apply for approval to market them between the second half of this year and 2022. Photo: Handout Akesobio aims to complete the trials of its lead drug candidates and apply for approval to market them between the second half of this year and 2022. Photo: Handout
Akesobio aims to complete the trials of its lead drug candidates and apply for approval to market them between the second half of this year and 2022. Photo: Handout
READ FULL ARTICLE